Australia - English - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd - sunitinib malate, quantity: 33.412 mg (equivalent: sunitinib, qty 25 mg) - capsule, hard - excipient ingredients: titanium dioxide; gelatin; iron oxide red; mannitol; croscarmellose sodium; magnesium stearate; pregelatinised maize starch; iron oxide black; iron oxide yellow; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia; potassium hydroxide - sunitinib msn is indicated for;,treatment of advanced renal cell carcinoma (rcc),treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net)

Australia - English - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd - sunitinib malate, quantity: 16.706 mg (equivalent: sunitinib, qty 12.5 mg) - capsule, hard - excipient ingredients: magnesium stearate; mannitol; titanium dioxide; croscarmellose sodium; gelatin; pregelatinised maize starch; iron oxide red; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia; potassium hydroxide - sunitinib msn is indicated for;,treatment of advanced renal cell carcinoma (rcc),treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net)

Australia - English - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd - sunitinib malate, quantity: 33.412 mg (equivalent: sunitinib, qty 25 mg) - capsule, hard - excipient ingredients: iron oxide yellow; mannitol; croscarmellose sodium; titanium dioxide; iron oxide red; gelatin; pregelatinised maize starch; magnesium stearate; iron oxide black; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia; potassium hydroxide - sunitinib msn is indicated for;,treatment of advanced renal cell carcinoma (rcc),treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net)

Israel - English - Ministry of Health

rafa laboratories ltd - budesonide - capsules - budesonide 3 mg - budesonide - budesonide - acute mild to moderate crohn’s disease with involvement of the ileum (twisted intestine) and/or ascending colon (part of large bowel). collagenous colitis.autoimmune hepatitis.

Israel - English - Ministry of Health

rafa laboratories ltd - budesonide - capsules - budesonide 3 mg - budesonide - acute mild to moderate crohn’s disease with involvement of the ileum (twisted intestine) and/or ascending colon (part of large bowel). collagenous colitis.autoimmune hepatitis.

Ireland - English - HPRA (Health Products Regulatory Authority)

strides pharma (cyprus) limited - colecalciferol - capsule, soft - colecalciferol

Ireland - English - HPRA (Health Products Regulatory Authority)

leo laboratories limited - alfacalcidol - capsule, soft - 1 microgram(s) - vitamin d and analogues; alfacalcidol

Ireland - English - HPRA (Health Products Regulatory Authority)

leo laboratories limited - alfacalcidol - capsule - 0.25 microgram(s) - vitamin d and analogues; alfacalcidol

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - phentermine, quantity: 40 mg - capsule, modified release - excipient ingredients: lactose monohydrate; sunset yellow fcf; liquid paraffin; magnesium stearate; erythrosine; iron oxide black; titanium dioxide; sodium polystyrene sulfonate; gelatin; sodium lauryl sulfate; silicon dioxide - duromine is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with duromine can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2) which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.

Ireland - English - HPRA (Health Products Regulatory Authority)

cheplapharm arzneimittel gmbh - alfacalcidol - capsule, soft - 0.25 microgram(s) - vitamin d and analogues; alfacalcidol